Real‐World Effectiveness of Sotrovimab in Patients Infected With SARS‐CoV‐2 Omicron Subvariant BA.2 in Western Sydney, Australia
Laboratory-based findings suggest that Sotrovimab is significantly less effective against emerging CARS-CoV-2 variants, however, clinical data is lacking. Here we examined the effectiveness of sotrovimab, in preventing emergency department (ED) presentation and subsequent hospitalization in high-risk subgroups of patients during the SARS-CoV-2 Delta and Omicron waves in Western Sydney, Australia (n = 515). Risk for ED attendance was comparable in Omicron patients, whether BA.1 or BA.2, compared to Delta patients (hazard ratio of 0.97 [0.36-2.64]). These findings highlight the need for caution when using in vitro findings to drive clinical practice, especially when the consequence is to withhold potentially lifesaving treatment.
Authors
- Joanne Medlin
- Eric Kalo (ORCID: https://orcid.org/0000-0002-6770-3857)
- Matthew O’Sullivan (ORCID: https://orcid.org/0000-0001-8783-5323)
- Golo Ahlenstiel (ORCID: https://orcid.org/0000-0003-0026-1457)
- L. Watson (ORCID: https://orcid.org/0000-0003-4489-3093)
- Gizelda Katz (ORCID: https://orcid.org/0000-0002-8572-8900)
- Scott Read (ORCID: https://orcid.org/0000-0001-6775-2061)
- Helen Crowther
- Jasmin Ellis
- Ziad Basyouni
- Vahid Karkvandi
Institutions
- The University of Sydney (AU)
- Taronga Conservation Society Australia (AU)
- Blacktown & Mount Druitt Hospital (AU)
- Westmead Hospital (AU)
- Sydney Local Health District (AU)
- Westmead Institute for Medical Research (AU)
- Western Sydney University (AU)
Publication Details
- Journal
- Journal of Medical Virology
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/jmv.70235
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Western Sydney University